Publicação

A new endolysin to combat Helicobacter pylori infections and gastric cancer prevention

Ver documento

Detalhes bibliográficos
Resumo:Helicobacter pylori is a Gram-negative microaerobic bacterium. This bacterium causes the most common chronic infection worldwide, affecting more than half of the world’s population, and is therefore considered the major human pathogen. H. pylori infections are difficult to cure, owing to this species rising resistance to standard antibiotic-based therapies. Recently, novel therapies are being developed to treat bacterial infections, such as therapy with bacteriophages (phages) and phage lytic proteins, named endolysins and holins. However, to date, there is minimal information about endolysins in the phage genomes of H. pylori. The main goal of this project is to develop a new therapy based on phage lytic proteins for the treatment of H. pylori infections. Bioinformatics analysis of H. pylori prophage genomes enabled the identification of seven potential lytic proteins coding sequences, which were cloned into pET-28a(+) and expressed in E. coli. Protein expression was only successful for HPy1Rgp29, HPy3RCgp27 and GFP-HPy1Rgp29. The previously reported endolysin ABgp46 from an Acinetobacter phage was also expressed as a positive control. For both assays carried out against H. pylori strain 11507, the positive control in question did not work, so it was not possible to draw any conclusions about the muralytic or antibacterial activity of the proteins considered. The lack of activity of the expressed proteins could be related to the lack of information concerning endolysins on H. pylori phages or the proteins chosen for this work may not be actual endolysins, among others reasons. To better understand the function of these proteins, more extensive work involving for example the fusion of GFP with these proteins might be an interesting approach in future works. In conclusion, while the technology used has great potential, as shown for other pathogens, further research is needed to assess the use of lytic proteins as a treatment for H. pylori infections.
Autores principais:Rocha, Maria Inês Pinto
Assunto:Helicobacter pylori Treatment Bacteriophages Lytic proteins Endolysin Holin Tratamento Bacteriófagos Proteínas líticas Endolisina Holina Engenharia e Tecnologia::Engenharia Médica
Ano:2023
País:Portugal
Tipo de documento:dissertação de mestrado
Tipo de acesso:acesso aberto
Instituição associada:Universidade do Minho
Idioma:inglês
Origem:RepositóriUM - Universidade do Minho
_version_ 1867439728858497024
author Rocha, Maria Inês Pinto
author_facet Rocha, Maria Inês Pinto
author_role author
contributor_name_str_mv Melo, Luís Daniel Rodrigues
Santos, Sílvio Roberto Branco
RepositóriUM - Universidade do Minho
country_str PT
creators_json_txt [{\"Person.name\":\"Rocha, Maria Inês Pinto\"}]
datacite.contributors.contributor.contributorName.fl_str_mv Melo, Luís Daniel Rodrigues
Santos, Sílvio Roberto Branco
RepositóriUM - Universidade do Minho
datacite.creators.creator.creatorName.fl_str_mv Rocha, Maria Inês Pinto
datacite.date.Accepted.fl_str_mv 2023-12-21T00:00:00Z
datacite.date.available.fl_str_mv 2025-01-15T14:27:21Z
datacite.date.embargoed.fl_str_mv 2025-01-15T14:27:21Z
datacite.rights.fl_str_mv http://purl.org/coar/access_right/c_abf2
datacite.subjects.subject.fl_str_mv Helicobacter pylori
Treatment
Bacteriophages
Lytic proteins
Endolysin
Holin
Tratamento
Bacteriófagos
Proteínas líticas
Endolisina
Holina
Engenharia e Tecnologia::Engenharia Médica
datacite.titles.title.fl_str_mv A new endolysin to combat Helicobacter pylori infections and gastric cancer prevention
dc.contributor.none.fl_str_mv Melo, Luís Daniel Rodrigues
Santos, Sílvio Roberto Branco
RepositóriUM - Universidade do Minho
dc.creator.none.fl_str_mv Rocha, Maria Inês Pinto
dc.date.Accepted.fl_str_mv 2023-12-21T00:00:00Z
dc.date.available.fl_str_mv 2025-01-15T14:27:21Z
dc.date.embargoed.fl_str_mv 2025-01-15T14:27:21Z
dc.format.none.fl_str_mv application/pdf
dc.identifier.none.fl_str_mv https://hdl.handle.net/1822/94466
dc.language.none.fl_str_mv eng
dc.rights.cclincense.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.none.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.rights.copyright.fl_str_mv openAccess
dc.subject.none.fl_str_mv Helicobacter pylori
Treatment
Bacteriophages
Lytic proteins
Endolysin
Holin
Tratamento
Bacteriófagos
Proteínas líticas
Endolisina
Holina
Engenharia e Tecnologia::Engenharia Médica
dc.title.fl_str_mv A new endolysin to combat Helicobacter pylori infections and gastric cancer prevention
dc.type.none.fl_str_mv http://purl.org/coar/resource_type/c_bdcc
description Helicobacter pylori is a Gram-negative microaerobic bacterium. This bacterium causes the most common chronic infection worldwide, affecting more than half of the world’s population, and is therefore considered the major human pathogen. H. pylori infections are difficult to cure, owing to this species rising resistance to standard antibiotic-based therapies. Recently, novel therapies are being developed to treat bacterial infections, such as therapy with bacteriophages (phages) and phage lytic proteins, named endolysins and holins. However, to date, there is minimal information about endolysins in the phage genomes of H. pylori. The main goal of this project is to develop a new therapy based on phage lytic proteins for the treatment of H. pylori infections. Bioinformatics analysis of H. pylori prophage genomes enabled the identification of seven potential lytic proteins coding sequences, which were cloned into pET-28a(+) and expressed in E. coli. Protein expression was only successful for HPy1Rgp29, HPy3RCgp27 and GFP-HPy1Rgp29. The previously reported endolysin ABgp46 from an Acinetobacter phage was also expressed as a positive control. For both assays carried out against H. pylori strain 11507, the positive control in question did not work, so it was not possible to draw any conclusions about the muralytic or antibacterial activity of the proteins considered. The lack of activity of the expressed proteins could be related to the lack of information concerning endolysins on H. pylori phages or the proteins chosen for this work may not be actual endolysins, among others reasons. To better understand the function of these proteins, more extensive work involving for example the fusion of GFP with these proteins might be an interesting approach in future works. In conclusion, while the technology used has great potential, as shown for other pathogens, further research is needed to assess the use of lytic proteins as a treatment for H. pylori infections.
dirty 0
eu_rights_str_mv openAccess
format masterThesis
fulltext.url.fl_str_mv https://repositorium.uminho.pt/bitstreams/348043cc-0156-4ff6-a1fb-ae64b68cae26/download
id rum_df08e1ad4684ceddc97fb54e2b04870e
identifier.url.fl_str_mv https://hdl.handle.net/1822/94466
instacron_str repositorium
institution Universidade do Minho
instname_str Universidade do Minho
language eng
network_acronym_str rum
network_name_str RepositóriUM - Universidade do Minho
oai_identifier_str oai:repositorium.uminho.pt:1822/94466
organization_str_mv urn:organizationAcronym:repositorium
person_str_mv Rocha, Maria Inês Pinto
publishDate 2023
reponame_str RepositóriUM - Universidade do Minho
repository_id_str urn:repositoryAcronym:rum
service_str_mv urn:repositoryAcronym:rum
spelling engporHelicobacter pylori is a Gram-negative microaerobic bacterium. This bacterium causes the most common chronic infection worldwide, affecting more than half of the world’s population, and is therefore considered the major human pathogen. H. pylori infections are difficult to cure, owing to this species rising resistance to standard antibiotic-based therapies. Recently, novel therapies are being developed to treat bacterial infections, such as therapy with bacteriophages (phages) and phage lytic proteins, named endolysins and holins. However, to date, there is minimal information about endolysins in the phage genomes of H. pylori. The main goal of this project is to develop a new therapy based on phage lytic proteins for the treatment of H. pylori infections. Bioinformatics analysis of H. pylori prophage genomes enabled the identification of seven potential lytic proteins coding sequences, which were cloned into pET-28a(+) and expressed in E. coli. Protein expression was only successful for HPy1Rgp29, HPy3RCgp27 and GFP-HPy1Rgp29. The previously reported endolysin ABgp46 from an Acinetobacter phage was also expressed as a positive control. For both assays carried out against H. pylori strain 11507, the positive control in question did not work, so it was not possible to draw any conclusions about the muralytic or antibacterial activity of the proteins considered. The lack of activity of the expressed proteins could be related to the lack of information concerning endolysins on H. pylori phages or the proteins chosen for this work may not be actual endolysins, among others reasons. To better understand the function of these proteins, more extensive work involving for example the fusion of GFP with these proteins might be an interesting approach in future works. In conclusion, while the technology used has great potential, as shown for other pathogens, further research is needed to assess the use of lytic proteins as a treatment for H. pylori infections.application/pdfporA new endolysin to combat Helicobacter pylori infections and gastric cancer preventionRocha, Maria Inês PintoMelo, Luís Daniel RodriguesSantos, Sílvio Roberto BrancoHostingInstitutionOrganizationalRepositóriUM - Universidade do Minhoe-mailmailto:repositorium@usdb.uminho.ptrepositorium@usdb.uminho.ptTID2037075592025-01-15T14:27:21Z2023-12-212023-102023-12-21T00:00:00ZHandlehttps://hdl.handle.net/1822/94466http://purl.org/coar/access_right/c_abf2open accessHelicobacter pyloriTreatmentBacteriophagesLytic proteinsEndolysinHolinTratamentoBacteriófagosProteínas líticasEndolisinaHolinahttp://www.oecd.org/science/inno/38235147.pdfFields of Science and Technology (FOS)Engenharia e Tecnologia::Engenharia Médica12713733 bytesliteraturehttp://purl.org/coar/resource_type/c_bdccmaster thesis2023-12-21http://creativecommons.org/licenses/by-nc-nd/4.0/openAccesshttp://purl.org/coar/access_right/c_abf2application/pdffulltexthttps://repositorium.uminho.pt/bitstreams/348043cc-0156-4ff6-a1fb-ae64b68cae26/download
spellingShingle A new endolysin to combat Helicobacter pylori infections and gastric cancer prevention
Rocha, Maria Inês Pinto
Helicobacter pylori
Treatment
Bacteriophages
Lytic proteins
Endolysin
Holin
Tratamento
Bacteriófagos
Proteínas líticas
Endolisina
Holina
Engenharia e Tecnologia::Engenharia Médica
status SINGLETON
subject.fl_str_mv Helicobacter pylori
Treatment
Bacteriophages
Lytic proteins
Endolysin
Holin
Tratamento
Bacteriófagos
Proteínas líticas
Endolisina
Holina
subject.other.fl_str_mv Engenharia e Tecnologia::Engenharia Médica
title A new endolysin to combat Helicobacter pylori infections and gastric cancer prevention
title_full A new endolysin to combat Helicobacter pylori infections and gastric cancer prevention
title_fullStr A new endolysin to combat Helicobacter pylori infections and gastric cancer prevention
title_full_unstemmed A new endolysin to combat Helicobacter pylori infections and gastric cancer prevention
title_short A new endolysin to combat Helicobacter pylori infections and gastric cancer prevention
title_sort A new endolysin to combat Helicobacter pylori infections and gastric cancer prevention
topic Helicobacter pylori
Treatment
Bacteriophages
Lytic proteins
Endolysin
Holin
Tratamento
Bacteriófagos
Proteínas líticas
Endolisina
Holina
Engenharia e Tecnologia::Engenharia Médica
topic_facet Helicobacter pylori
Treatment
Bacteriophages
Lytic proteins
Endolysin
Holin
Tratamento
Bacteriófagos
Proteínas líticas
Endolisina
Holina
Engenharia e Tecnologia::Engenharia Médica
url https://hdl.handle.net/1822/94466
visible 1